Palatin offering to fund bremelanotide for female sexual dysfunction
This article was originally published in Scrip
Executive Summary
Palatin Technologies has announced the pricing of its public offering of 23 million units at $1 per unit, and says that it expects net proceeds of the offering to be $21 million after deducting underwriting discounts and commissions. The offering was led by Roth Capital Partners, with Madison Williams & Co.